Long-term treatment of decompensated cirrhosis with human albumin improves survival

(European Association for the Study of the Liver) Results from the ANSWER study showed that long-term administration of human albumin improves the survival rate of patients with decompensated cirrhosis. The study, presented at The International Liver Congress ™ 2017 in Amsterdam, The Netherlands, demonstrated that treatment with human albumin also improved the management of ascites (accumulation of fluid in the abdominal cavity) and quality of life, and reduced the incidence of severe complications of the disease and the need for hospitalization.
Source: EurekAlert! - Social and Behavioral Science - Category: Global & Universal Source Type: news